DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Brown Michael Jon

Heller Bridgette P

Collins Richard Alexander

Leach Jacob Steven

Malady Kyle

Stern Sadie

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-positioned to deliver significant upside potential despite trading below analyst price targets.

9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time

DexCom, a leader in continuous glucose monitoring (CGM) devices, is gaining strong analyst support with 20 Buy ratings versus 4 Sell/Hold ratings and ~40% upside potential. The company beat Q1 2026 earnings expectations with $1.2B in quarterly revenue (up 15% YoY), improved margins, and $2.4B in cash. Key catalysts include the recent G7 15-Day CGM product launch, expansion into non-insulin users via the Stelo line, and manufacturing capacity expansion driving margin improvements.

DexCom Inc (DXCM) Stock Price, Analysis & Trade Signals